Seoulin Bioscience Co Ltd
KOSDAQ:038070
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Seoulin Bioscience Co Ltd
Cash from Financing Activities
Seoulin Bioscience Co Ltd
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Seoulin Bioscience Co Ltd
KOSDAQ:038070
|
Cash from Financing Activities
₩12.2B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
22%
|
|
|
Celltrion Inc
KRX:068270
|
Cash from Financing Activities
₩339.3B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
5%
|
CAGR 10-Years
10%
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Cash from Financing Activities
₩123.8B
|
CAGR 3-Years
30%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Cash from Financing Activities
₩3.9B
|
CAGR 3-Years
-46%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash from Financing Activities
₩155.6B
|
CAGR 3-Years
276%
|
CAGR 5-Years
15%
|
CAGR 10-Years
103%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Cash from Financing Activities
₩32.5B
|
CAGR 3-Years
91%
|
CAGR 5-Years
122%
|
CAGR 10-Years
N/A
|
|
Seoulin Bioscience Co Ltd
Glance View
SeouLin Bioscience Co., Ltd. engages in the provision of lifescience total solutions. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2005-10-25. The firm mainly engages in research and development of reagents, such as deoxyribonucleic acid (DNA) chips, which are used for gene therapy, clinical diagnosis, organs transplantation and biopsy; stem cells, which are used for treatment of incurable diseases, Alzheimer disease and others, and next-generation biotechnology drugs. The firm supplies its products under the brand name MyLab. The company also imports bio research equipment from Thermo Fisher, Affymetrix, Sarstedt and others, and markets in the domestic market. In addition, the Company engages in the real estate rental business.
See Also
What is Seoulin Bioscience Co Ltd's Cash from Financing Activities?
Cash from Financing Activities
12.2B
KRW
Based on the financial report for Sep 30, 2025, Seoulin Bioscience Co Ltd's Cash from Financing Activities amounts to 12.2B KRW.
What is Seoulin Bioscience Co Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
22%
The average annual Cash from Financing Activities growth rates for Seoulin Bioscience Co Ltd have been -25% over the past three years , and 22% over the past ten years .
